Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAspirus Arise Aliqopa Coverage Prior Auth Update |…
    Ask Trek AI about this page
    CurrentAspirus ArisePOLICY: Oncology (Injectable) - Aliqopa Utilization Management Medical Policy

    Aliqopa (copanlisib IV) Utilization Management Medical Policy

    Customize your policy alerts

    Sign up for Aspirus Arise POLICY: Oncology (Injectable) - Aliqopa Utilization Management Medical Policy alerts

    Get alerted when POLICY: Oncology (Injectable) - Aliqopa Utilization Management Medical Policy changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, dosing, and restrictions for Aliqopa (copanlisib IV) for Aspirus Medicare Plans; applies to providers prescribing or requesting coverage for Aliqopa.

    Policy Summary
    PayerAspirus Arise
    PolicyAliqopa (copanlisib IV) Utilization Management Medical Policy
    Policy CodePolicy POLICY: Oncology (Injectable) - Aliqopa Utilization Management Medical Policy
    Change TypeClarified coverage pathway after product withdrawal
    Effective DateJan 1, 2021
    Last ReviewSep 15, 2025
    Next Review DateSep 15, 2025
    Key ActionObtain prior authorization and document patient age, current receipt of Aliqopa, and >2 prior systemic therapies to qualify for approval.
    SourceLink
    POLICY UPDATE CHANGES

    Policy notes Bayer voluntarily withdrew Aliqopa from the U.S. market and the FDA withdrawal of the NDA, and retains coverage pathways for patients currently receiving therapy.

    1 yearapproval duration for covered indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    60 mgmaximum per-dose IV dosing
    >2required prior systemic therapies for approval
    All Aspirus Medicare Plansplans covered by this policy

    Recommended Authorization Criteria

    inv-01: Initial Therapy - Follicular Lymphoma

    Covered when ALL of the following are met:

    FDA-Approved Indication - Follicular Lymphoma: A) Patient is > 18 years of age; AND B) Patient is currently receiving Aliqopa; AND C) Patient has received > 2 prior systemic therapies (examples include bendamustine, cyclophosphamide, doxorubicin, vincristine, rituximab products, obinutuzumab); AND D) Aliqopa is prescribed by or in consultation with an oncologist.Approve for 1 year; dosing up to 60 mg IV administered up to three times in each 28-day cycle

    Examples of systemic therapies listed in policy include bendamustine, cyclophosphamide, doxorubicin, vincristine, rituximab products, obinutuzumab.

    inv-02: Other Supported Indication - Marginal Zone Lymphoma

    Covered when ALL of the following are met (applies to marginal zone lymphoma subtypes):

    Marginal Zone Lymphoma: A) Patient is > 18 years of age; AND B) Patient is currently receiving Aliqopa; AND C) [criterion formatting in source omitted but implied]; AND D) Patient has received > 2 prior systemic therapies (examples include bendamustine, cyclophosphamide, doxorubicin, vincristine, rituximab products, obinutuzumab); AND E) Aliqopa is prescribed by or in consultation with an oncologist.Approve for 1 year; dosing up to 60 mg IV administered up to three times in each 28-day cycle

    Includes extranodal (stomach and nongastric), nodal, and splenic marginal zone lymphoma.

    Coverage of Aliqopa (copanlisib) is not recommended for circumstances that are not specifically listed in the Recommended Authorization Criteria. Criteria will be updated as new published data become available.

    As reflected in current guideline and policy guidance, the National Comprehensive Cancer Network (NCCN) B‑Cell Lymphoma guidelines (version 2.2025) no longer recommend Aliqopa for relapsed/refractory follicular lymphoma (grade 1 or 2) and for multiple marginal zone lymphoma subtypes (extranodal stomach, extranodal nongastric, splenic, and nodal). Consistent with this guidance and the document change note, the policy limits approvals to the specific indications and patient populations listed in the Recommended Authorization Criteria and will be updated if new evidence warrants broader use.

    Dosing and Regimens

    RegimenIndicationAuthorization DurationCoverage
    Copanlisib 60 mg IV up to three times per 28-day cycleRelapsed follicular lymphoma in adults currently receiving Aliqopa after > 2 prior systemic therapiesApprove for 1 yearCovered
    RegimenIndicationAuthorization DurationCoverage
    Copanlisib 60 mg IV up to three times per 28-day cycleMarginal zone lymphoma subtypes (extranodal stomach and nongastric, nodal, splenic) in adults currently receiving Aliqopa after > 2 prior systemic therapiesApprove for 1 yearCovered

    Coding and Related Operational Notes

    Coding — none listedmixed
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes listed in policy
    Prior systemic therapies — threshold
    Required prior systemic therapies> 2 prior systemic therapies
    Examples of systemic therapiesbendamustine; cyclophosphamide; doxorubicin; vincristine; rituximab products (e.g., Rituxan, biosimilars); obinutuzumab (Gazyva)
    Applies to approvals forRelapsed follicular lymphoma and marginal zone lymphoma subtypes where patient is currently receiving Aliqopa

    Provider Requirements and Authorization Workflow

    Prior Authorization

    Prior authorization required

    Prior authorization is recommended for medical benefit coverage of Aliqopa; approval is recommended only when the patient meets the specified Criteria and Dosing for the listed indications. Approvals are provided for the duration noted in the policy and require Aliqopa to be prescribed by or in consultation with a physician who specializes in the condition being treated.

    Step Therapy

    Prior therapy requirement

    Approval requires that the patient has received greater than two prior systemic therapies before qualifying under the policy; examples of systemic therapies listed include bendamustine, cyclophosphamide, doxorubicin, vincristine, rituximab products (e.g., Rituxan, biosimilars), and Gazyva (obinutuzumab).

    Therapy Setting and Intent

    inv-13: salvage

    Line of therapy: Patient must have received greater than two prior systemic therapies before qualifying for approval.

    Background and Drug Information

    Aliqopa (copanlisib intravenous infusion) is a PI3K kinase inhibitor indicated historically for the treatment of relapsed follicular lymphoma in adults who have received at least two prior systemic therapies. The policy retains limited, operational coverage pathways for patients currently receiving Aliqopa and specifies authorization requirements including patient age, documentation of prior therapies, and oncologist involvement.

    Drug Definition

    Aliqopa (copanlisib) — drug definition
    Drug name (generic)Copanlisib
    Brand nameAliqopa
    Formulation and routeIntravenous infusion (administered IV)
    Mechanism of action / drug classPan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor (kinase inhibitor)
    Indicated use per policyTreatment of relapsed follicular lymphoma in adults who have received at least two prior systemic therapies; limited coverage retained for patients currently receiving therapy
    Policy Summary
    PayerAspirus Arise
    PolicyAliqopa (copanlisib IV) Utilization Management Medical Policy
    Policy CodePolicy POLICY: Oncology (Injectable) - Aliqopa Utilization Management Medical Policy
    Change TypeClarified coverage pathway after product withdrawal
    Effective DateJan 1, 2021
    Last ReviewSep 15, 2025
    Next Review DateSep 15, 2025
    Key ActionObtain prior authorization and document patient age, current receipt of Aliqopa, and >2 prior systemic therapies to qualify for approval.
    SourceLink
    On This Page
    Recommended Authorization CriteriaDosing and RegimensCoding and Related Operational NotesProvider Requirements and Authorization WorkflowTherapy Setting and IntentBackground and Drug InformationDrug Definition
    Documentation Required

    Required documentation

    Documentation must demonstrate that the patient is > 18 years of age, is currently receiving Aliqopa, and has received > 2 prior systemic therapies (with types/examples documented); also document that Aliqopa is prescribed by or in consultation with an oncologist per the policy criteria.

    Denial Risk

    Denial triggers

    Requests that do not meet the Recommended Authorization Criteria or that are for indications or circumstances not listed will not be recommended for approval.

    • Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria.
    • Approvals are limited to patients meeting the policy's listed criteria and dosing.